Noema Pharma
Founded 2019 · 35 employees on LinkedIn · 11 known investors
Find your way into Noema Pharma
1,092 people in our graph share verified history with the Noema Pharma team — schools, employers, funds. One of them is your warm intro.
Teresa Chanunlockedknows Rob Lasser · together at Johnson & Johnson (overlapped)
knows the team · via Yale School of Medicine
×3knows the team · via Dartmouth College
knows the team · via Harvard Medical School
knows the team · via Johnson & Johnson
knows the team · via Assemblybio
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs. The company works with patients, caregivers, and healthcare professionals throughout discovery and clinical development.
Founders & leadership
IL
Ilise LombardoinChief Executive Officer
VK
Volker KnappertzinExecutive Vice President of Research & DevelopmentBoard-certified neurologist with a medical degree from Cologne University and neurology training at Yale University and Wake Forest University. Knappertz held senior R&D and clinical roles at GW Pharmaceuticals (where he contributed to Epidiolex's global approvals), Aurinia Pharmaceuticals, Teva Pharmaceuticals, Bayer, AstraZeneca, and Medimmune before becoming Executive Vice President of Research & Development at Noema Pharma.
MS
Michael SamarinChief Financial OfficerMichael Samar is Chief Financial Officer at Noema Pharma, a biopharmaceutical company developing oral small molecule therapeutics for neurological disorders. He has held executive finance roles overseeing capital raising, IPOs, mergers and acquisitions, and financial operations in the pharmaceutical and biotech sectors.
RL
Rob LasserinChief Medical OfficerRob Lasser is a board-certified psychiatrist with an MD and MBA who has conducted clinical research in late-life depression and dementia while holding medical leadership roles at major pharmaceutical companies overseeing neuroscience development programs. He has maintained a clinical practice in geriatric psychiatry and psychopharmacology for nearly two decades and has published over 80 peer-reviewed articles in psychiatry and related fields.
Investors · 11
BioMedPartnersBasel · $648K – $6.5M
Jeito CapitalParis
Roche Venture FundBasel · $648K – $3.2M
Sofinnova PartnersParis · $540K – $27M
EQTreported · 2 sourcesNew York
EQT Life Sciencesreported · 2 sourcesLuxembourg · $11M – $66M
Forbionreported · 2 sourcesNaarden
Gilde Healthcarereported · 2 sourcesUtrecht · $1.1M – $55M
InvusreportedNew York
Also in the syndicate · 2
Polaris PartnersUPMC Enterprises
Funding
SEC filings, press & company announcements$112M disclosed across 1 of 3 rounds · 2023–2025
- Undisclosed amountextension of its series B funding roundNov 2025
EQT Life Sciences (lead), EQT, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, Sofinnova Partners, UPMC Enterprises
Source ↗ - Undisclosed amountSeries BDec 2024Source ↗
- $112MSeries BMar 2023 · 3 sources
Forbion (lead), Jeito Capital (lead), Gilde Healthcare, Invus, Polaris Partners, Sofinnova Partners, UPMC Enterprises
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 5
by search overlap
NMD Pharma5 shared keywordsNMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions. Its lead candidate, ignaseclant (NMD670), is in clinical development for Charcot-Marie-Tooth disease, generalized myasthenia gravis, and spinal muscular atrophy.</parameter>
<parameter name="founders">[]
Forbion Capital4 shared keywordsA venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.
Doximity3 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Veeva3 shared keywordsVeeva Clinical Platform is a cloud-based suite of connected applications for running clinical trials, covering clinical operations, clinical data, research sites, and patients. It serves biopharma sponsors, clinical research sites, and patients across trial management, data capture, and disclosures.
Nrxpharma3 shared keywordsNRx Pharmaceuticals develops medicines for people with unmet medical needs, focused on making untreatable diseases treatable. It operates in the pharmaceutical and biotech industry.
Companies competing with Noema Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Noema Pharma do?
- Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs. The company works with patients, caregivers, and healthcare professionals throughout discovery and clinical development.
- Who are Noema Pharma's investors?
- Noema Pharma's investors include BioMedPartners, Jeito Capital, Roche Venture Fund, Sofinnova Partners, EQT, EQT Life Sciences, Forbion, Gilde Healthcare and 1 more.
- How much funding has Noema Pharma raised?
- Noema Pharma has disclosed $112M raised across 1 of its 3 known rounds.